S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Total Liabilities
ÂĄ334.6m
CAGR 3-Years
90%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities
ÂĄ16B
CAGR 3-Years
13%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Liabilities
ÂĄ7.9B
CAGR 3-Years
20%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities
ÂĄ3B
CAGR 3-Years
47%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities
ÂĄ23.3B
CAGR 3-Years
27%
CAGR 5-Years
32%
CAGR 10-Years
64%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities
ÂĄ504.4m
CAGR 3-Years
72%
CAGR 5-Years
51%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Liabilities?
Total Liabilities
334.6m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Total Liabilities amounts to 334.6m CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
90%

Over the last year, the Total Liabilities growth was 18%. The average annual Total Liabilities growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 90% over the past three years .

Back to Top